3 days popular7 days popular1 month popular3 months popular

Primates protected from deadly Marburg virus

For the first time, scientists have demonstrated the effectiveness of a small-molecule drug in protecting nonhuman primates from the lethal . Their work, published online in the journal Nature, is the result of a continuing collaboration between Army scientists and industry partners that also shows promise for treating a broad range of other viral diseases.

According to senior author , the drug, known as BCX4430, protected cynomolgous macaques from Marburg virus infection when administered by injection as long as 48 hours post-infection. Bavari and his team at the U.S. Army Medical Research Institute of Infectious Diseases () also found that BCX4430 protected guinea pigs exposed to Marburg virus by the inhalation route.

Developed by , , BCX4430 also demonstrated activity against a broad range of other RNA viruses, including the emerging viral pathogen Middle East respiratory syndrome coronavirus (MERS-CoV), when tested in cell culture.

“This study demonstrates the importance of government-industry collaboration,” said COL Erin P. Edgar, commander of USAMRIID. “Developing filovirus medical countermeasures is a top biodefense priority for the United States. When federal assets like USAMRIID team up with cutting-edge partners in private industry, we can make real progress toward achieving that goal.”

The paper’s first author, Travis K. Warren of USAMRIID, said findings from the work show the drug acts by interfering with the internal “machinery” of the Marburg virus, preventing it from replicating its genetic material. He said the team is currently planning additional studies to determine whether the therapeutic window can be extended beyond 48 hours. In addition, BioCryst plans to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials, according to Warren.

Ebola and Marburg cause hemorrhagic fever with case fatality rates as high as 90 percent in humans. The viruses, which are infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), are of concern both as global health threats and as potential agents of biological warfare or terrorism. Currently there are no available vaccines or therapies. Research on both viruses is conducted in Biosafety Level 4, or maximum containment, laboratories, where investigators wear positive-pressure “space suits” and breathe filtered air as they work.


Collaborators on the study included USAMRIID, Fort Detrick, Md.; BioCryst Pharmaceuticals, Inc. Durham, N.C.; and MedExpert Consulting, Inc., Indialantic, Fla.

The work was supported by The Joint Science and Technology Office for Chemical and Biological Defense of the Defense Threat Reduction Agency. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Department of Health and Human Services, also provided partial support for in vitro studies.

Protection against filovirus diseases by a novel broad-spectrum nucleoside analog BCX4430: Nature, published online 2 Mar 2014 (1800 London time/1300 Eastern US time). DOI: 10.1038/nature13027. Travis K. Warren, Jay Wells, Rekha G. Panchal, Kelly S. Stuthman, Nicole L. Garza, Sean A. Van Tongeren, Lian Dong, Cary J. Retterer, Brett P. Eaton, Gianluca Pegoraro, Shelley Honnold, Shanta Bantia, Pravin Kotian, Xilin Chen, Brian R. Taubenheim, Lisa S. Welch, Dena M. Minning, Yarlagadda S. Babu, William P. Sheridan, and Sina Bavari.

US Army Medical Research Institute of Infectious Diseases